These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 30099641

  • 1. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.
    Tsukamoto S, Mavrogenis AF, Leone G, Righi A, Akahane M, Tanzi P, Kido A, Honoki K, Tanaka Y, Donati DM, Errani C.
    Int Orthop; 2019 Feb; 43(2):483-489. PubMed ID: 30099641
    [Abstract] [Full Text] [Related]

  • 2. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 3. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.
    Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
    [Abstract] [Full Text] [Related]

  • 4. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 5. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
    Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Ciani G, Righi A, Akahane M, Honoki K, Tanaka Y, Donati DM, Errani C.
    Orthopedics; 2020 Sep 01; 43(5):284-291. PubMed ID: 32745221
    [Abstract] [Full Text] [Related]

  • 6. How safe and effective is denosumab for bone giant cell tumour?
    Errani C, Tsukamoto S, Mavrogenis AF.
    Int Orthop; 2017 Nov 01; 41(11):2397-2400. PubMed ID: 28646421
    [Abstract] [Full Text] [Related]

  • 7. Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use.
    Fujihara N, Hamada S, Yoshida M, Tsukushi S.
    BMJ Case Rep; 2021 Nov 11; 14(11):. PubMed ID: 34764115
    [Abstract] [Full Text] [Related]

  • 8. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 9. The risk of neurological deterioration while using neoadjuvant denosumab on patients with giant cell tumor of the spine presenting with epidural disease: a meta-analysis of the literature.
    Al Farii H, McChesney G, Patel SS, Rhines LD, Lewis VO, Bird JE.
    Spine J; 2024 Jun 21; 24(6):1056-1064. PubMed ID: 38301904
    [Abstract] [Full Text] [Related]

  • 10. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
    Agarwal MG, Gundavda MK, Gupta R, Reddy R.
    Clin Orthop Relat Res; 2018 Sep 21; 476(9):1773-1782. PubMed ID: 30794215
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May 21; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

  • 12. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
    Sambri A, Medellin MR, Errani C, Campanacci L, Fujiwara T, Donati D, Parry M, Grimer R.
    J Orthop Sci; 2020 May 21; 25(3):513-519. PubMed ID: 31155442
    [Abstract] [Full Text] [Related]

  • 13. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 21; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 14. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E.
    Lancet Oncol; 2019 Dec 21; 20(12):1719-1729. PubMed ID: 31704134
    [Abstract] [Full Text] [Related]

  • 15. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL, Hansen RL, Jørgensen PH.
    Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237
    [Abstract] [Full Text] [Related]

  • 16. Giant cell tumour of bone in the denosumab era.
    van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H.
    Eur J Cancer; 2017 May 05; 77():75-83. PubMed ID: 28365529
    [Abstract] [Full Text] [Related]

  • 17. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R.
    World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843
    [Abstract] [Full Text] [Related]

  • 18. Denosumab Does Not Decrease Local Recurrence in Giant Cell Tumor of Bone Treated With En Bloc Resection.
    Tsukamoto S, Mavrogenis AF, Tanaka Y, Kido A, Kawaguchi M, Errani C.
    Orthopedics; 2021 Nov 04; 44(6):326-332. PubMed ID: 34618637
    [Abstract] [Full Text] [Related]

  • 19. Malignant Transformation of a Giant Cell Tumor of Bone Treated with Denosumab: A Case Report.
    Park A, Cipriano CA, Hill K, Kyriakos M, McDonald DJ.
    JBJS Case Connect; 2016 Nov 04; 6(3):e78. PubMed ID: 29252655
    [Abstract] [Full Text] [Related]

  • 20. Recurrent giant cell tumour of the maxillary sinus and pterygoid process treated with denosumab.
    Rosa D, Dias RB, Salvador JC, Borges A.
    BMJ Case Rep; 2018 Sep 08; 2018():. PubMed ID: 30196254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.